Amir Vajdi
Research Subjects
Amir Vajdi has a total of 201 co-authors. Here are the top co-authors by number of shared publications:
- Erik H. Knelson
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
37 shared publications David A. Barbie
Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA
32 shared publicationsDeli Hong
32 shared publicationsMichael Y. Tolstorukov
32 shared publicationsMatthew G. Oser
30 shared publications- Armando Santoro
Istituto di Ricovero e Cura a Carattere Scientifico Humanitas Research Hospital, Rozzano (Milan), Italy
29 shared publications
Latest Publications
- Open Access
- 26 March 2026
- Published by American Association for Cancer Research (AACR)
Data from Lenvatinib plus Pembrolizumab for Patients with Previously Treated Advanced Gastric, Biliary Tract, or Pancreatic Cancer: Results from the Phase II LEAP-005 Study
Purpose:Patients with gastric cancer, biliary tract cancer (BTC), and pancreatic ductal adenocarcinoma (PDAC) have poor survival outcomes and limited second- or later-line treatment options. Certain drugs targeting vascular endothelial growth factor (VEGF) or programmed cell death protein 1 (PD-1) signaling pathways are currently used in these cancers in specific circumstances; however, there remains a need for novel treatment combinations. LEAP-005 is a multicohort, open-label, phase II study that evaluated lenvatinib (multitargeted inhibitor of tyrosine kinases, including VEGF) plus pembrolizumab (anti–PD-1 monoclonal antibody) in select previously treated solid tumors.Patients and Methods:Participants with previously treated, advanced gastric cancer, BTC, and PDAC were enrolled in cohorts C, F, and G of LEAP-005, respectively, and received lenvatinib 20 mg/day orally plus pembrolizumab 200 mg i.v. every 3 weeks. Primary endpoints were objective response rate (ORR) and safety.Results:Of 99, 102, and 103 total participants enrolled in cohorts C, F, and G, respectively, median times from first dose of study treatment to data cutoff (February 6, 2023) were 23.7, 24.2, and 19.5 months. ORRs (95% confidence interval) by blinded independent central review were 15.2% (8.7%–23.8%) in cohort C, 17.6% (10.8%–26.4%) in cohort F, and 7.8% (3.4%–14.7%) in cohort G. Grade 3 to 5 treatment-related adverse events occurred in 54.5% of participants in cohort C, and grade 3 to 4 (no grade 5) occurred in 60.8% and 59.2% of participants in cohorts F and G, respectively.Conclusions:Lenvatinib plus pembrolizumab demonstrated modest antitumor activity and a manageable safety profile in previously treated, advanced gastric cancer, BTC, and PDAC.Significance:In the phase II LEAP-005 study, lenvatinib plus pembrolizumab showed modest antitumor activity and a manageable safety profile in participants with previously treated gastrointestinal-related cancers. Exploratory analyses in participants with BTC indicated higher ORRs in participants with targetable alterations versus those without.
- 26 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Lenvatinib plus Pembrolizumab for Patients with Previously Treated Advanced Gastric, Biliary Tract, or Pancreatic Cancer: Results from the Phase II LEAP-005 Study
Purpose:Patients with gastric cancer, biliary tract cancer (BTC), and pancreatic ductal adenocarcinoma (PDAC) have poor survival outcomes and limited second- or later-line treatment options. Certain drugs targeting vascular endothelial growth factor (VEGF) or programmed cell death protein 1 (PD-1) signaling pathways are currently used in these cancers in specific circumstances; however, there remains a need for novel treatment combinations. LEAP-005 is a multicohort, open-label, phase II study that evaluated lenvatinib (multitargeted inhibitor of tyrosine kinases, including VEGF) plus pembrolizumab (anti–PD-1 monoclonal antibody) in select previously treated solid tumors.Patients and Methods:Participants with previously treated, advanced gastric cancer, BTC, and PDAC were enrolled in cohorts C, F, and G of LEAP-005, respectively, and received lenvatinib 20 mg/day orally plus pembrolizumab 200 mg i.v. every 3 weeks. Primary endpoints were objective response rate (ORR) and safety.Results:Of 99, 102, and 103 total participants enrolled in cohorts C, F, and G, respectively, median times from first dose of study treatment to data cutoff (February 6, 2023) were 23.7, 24.2, and 19.5 months. ORRs (95% confidence interval) by blinded independent central review were 15.2% (8.7%–23.8%) in cohort C, 17.6% (10.8%–26.4%) in cohort F, and 7.8% (3.4%–14.7%) in cohort G. Grade 3 to 5 treatment-related adverse events occurred in 54.5% of participants in cohort C, and grade 3 to 4 (no grade 5) occurred in 60.8% and 59.2% of participants in cohorts F and G, respectively.Conclusions:Lenvatinib plus pembrolizumab demonstrated modest antitumor activity and a manageable safety profile in previously treated, advanced gastric cancer, BTC, and PDAC.Significance:In the phase II LEAP-005 study, lenvatinib plus pembrolizumab showed modest antitumor activity and a manageable safety profile in participants with previously treated gastrointestinal-related cancers. Exploratory analyses in participants with BTC indicated higher ORRs in participants with targetable alterations versus those without.
- Open Access
- 26 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from Lenvatinib plus Pembrolizumab for Patients with Previously Treated Advanced Gastric, Biliary Tract, or Pancreatic Cancer: Results from the Phase II LEAP-005 Study
Association between TMB and objective response in participants with biliary tract cancer (cohort F)
- 26 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from Lenvatinib plus Pembrolizumab for Patients with Previously Treated Advanced Gastric, Biliary Tract, or Pancreatic Cancer: Results from the Phase II LEAP-005 Study
Association between TMB and objective response in participants with biliary tract cancer (cohort F)
- Open Access
- 26 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 10 from Lenvatinib plus Pembrolizumab for Patients with Previously Treated Advanced Gastric, Biliary Tract, or Pancreatic Cancer: Results from the Phase II LEAP-005 Study
RAS signature scores by tumor KRAS mutation status in participants with biliary tract cancer (cohort F)
- 26 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 10 from Lenvatinib plus Pembrolizumab for Patients with Previously Treated Advanced Gastric, Biliary Tract, or Pancreatic Cancer: Results from the Phase II LEAP-005 Study
RAS signature scores by tumor KRAS mutation status in participants with biliary tract cancer (cohort F)
- Open Access
- 26 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 7 from Lenvatinib plus Pembrolizumab for Patients with Previously Treated Advanced Gastric, Biliary Tract, or Pancreatic Cancer: Results from the Phase II LEAP-005 Study
PFS and OS by TcellinfGEP in participants with biliary tract cancer (cohort F)
- 26 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 7 from Lenvatinib plus Pembrolizumab for Patients with Previously Treated Advanced Gastric, Biliary Tract, or Pancreatic Cancer: Results from the Phase II LEAP-005 Study
PFS and OS by TcellinfGEP in participants with biliary tract cancer (cohort F)
- Open Access
- 26 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Lenvatinib plus Pembrolizumab for Patients with Previously Treated Advanced Gastric, Biliary Tract, or Pancreatic Cancer: Results from the Phase II LEAP-005 Study
Response in tumor biomarker subgroups among participants with biliary tract cancer (cohort F)
- 26 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Lenvatinib plus Pembrolizumab for Patients with Previously Treated Advanced Gastric, Biliary Tract, or Pancreatic Cancer: Results from the Phase II LEAP-005 Study
Response in tumor biomarker subgroups among participants with biliary tract cancer (cohort F)
- Open Access
- 26 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 6 from Lenvatinib plus Pembrolizumab for Patients with Previously Treated Advanced Gastric, Biliary Tract, or Pancreatic Cancer: Results from the Phase II LEAP-005 Study
Immune-mediated adverse events and clinically significant adverse events for lenvatinib by grade in cohort F
- 26 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 6 from Lenvatinib plus Pembrolizumab for Patients with Previously Treated Advanced Gastric, Biliary Tract, or Pancreatic Cancer: Results from the Phase II LEAP-005 Study
Immune-mediated adverse events and clinically significant adverse events for lenvatinib by grade in cohort F
- Open Access
- 26 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from Lenvatinib plus Pembrolizumab for Patients with Previously Treated Advanced Gastric, Biliary Tract, or Pancreatic Cancer: Results from the Phase II LEAP-005 Study
Immune-mediated adverse events and clinically significant adverse events for lenvatinib by grade in cohort C
- 26 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from Lenvatinib plus Pembrolizumab for Patients with Previously Treated Advanced Gastric, Biliary Tract, or Pancreatic Cancer: Results from the Phase II LEAP-005 Study
Immune-mediated adverse events and clinically significant adverse events for lenvatinib by grade in cohort C
- Open Access
- 26 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 9 from Lenvatinib plus Pembrolizumab for Patients with Previously Treated Advanced Gastric, Biliary Tract, or Pancreatic Cancer: Results from the Phase II LEAP-005 Study
Association between RAS and objective response in participants with biliary tract cancer (cohort F)
- 26 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 9 from Lenvatinib plus Pembrolizumab for Patients with Previously Treated Advanced Gastric, Biliary Tract, or Pancreatic Cancer: Results from the Phase II LEAP-005 Study
Association between RAS and objective response in participants with biliary tract cancer (cohort F)
- Open Access
- 26 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 8 from Lenvatinib plus Pembrolizumab for Patients with Previously Treated Advanced Gastric, Biliary Tract, or Pancreatic Cancer: Results from the Phase II LEAP-005 Study
Association between TcellinfGEP and objective response in participants with biliary tract cancer (cohort F)
- 26 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 8 from Lenvatinib plus Pembrolizumab for Patients with Previously Treated Advanced Gastric, Biliary Tract, or Pancreatic Cancer: Results from the Phase II LEAP-005 Study
Association between TcellinfGEP and objective response in participants with biliary tract cancer (cohort F)
- Open Access
- 26 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from Lenvatinib plus Pembrolizumab for Patients with Previously Treated Advanced Gastric, Biliary Tract, or Pancreatic Cancer: Results from the Phase II LEAP-005 Study
Hypothesis testing of associations between TcellinfGEP and non TcellinfGEP consensus signatures, and clinical outcomes in participants with biliary tract cancer (cohort F)
- 26 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from Lenvatinib plus Pembrolizumab for Patients with Previously Treated Advanced Gastric, Biliary Tract, or Pancreatic Cancer: Results from the Phase II LEAP-005 Study
Hypothesis testing of associations between TcellinfGEP and non TcellinfGEP consensus signatures, and clinical outcomes in participants with biliary tract cancer (cohort F)